Physician profile
Benjamin H Bloom
NPI 1578676359
$1,633.40
in general payments reported to CMS, 2019-2025
17 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $38.00 · 2021: $73.52 · 2022: $190 · 2023: $483 · 2024: $293 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $272.63 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $228.91 | 2024-2025 | Xiidra, Miebo |
| Alcon Vision LLC | $185.23 | 2022-2025 | Hydrus Microstent, Clareon, Eysuvis |
| Genentech USA, INC. | $185.08 | 2019 | |
| Alimera Sciences, INC. | $161.97 | 2021-2023 | Iluvien |
| Amgen INC. | $126.68 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $122.97 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $113.03 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $53.32 | 2023 | Tyrvaya |
| Merz Pharmaceuticals, LLC | $34.82 | 2022 | |
| Abbvie INC. | $32.75 | 2025 | |
| Coopervision INC. | $27.63 | 2025 | Myday Contact Lens |
| Eyevance Pharmaceuticals LLC | $19.30 | 2020 | |
| Rxsight INC | $19.02 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Apellis Pharmaceuticals, INC. | $18.86 | 2023 | Syfovre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.70 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.